QPCT has been identified as a potential therapeutic target due to its role in modulating immune cell–mediated phagocytosis of tumor cells, and considerable efforts have been made to develop small-molecule inhibitors against this enzyme (33, 34). The gene discussed is QPCT; the disease is neoplasm.